HemaSphere (Aug 2023)
P571: OUTPATIENT INITIATION OF VENETOCLAX-AZACITIDINE FOR SELECTED ACUTE MYELOID LEUKEMIA PATIENTS IS FEASIBLE AND SAFE: A REAL WORLD SINGLE CENTER ANALYSIS
- Roi Gat,
- Miri Neeman,
- Shai Levi,
- Mor Levi,
- Nili Eilati,
- Yotam Bronstein,
- Tamir Shragai,
- Tsipora Neuman,
- Yafit Segman,
- Roy Vitkon,
- Moshe Mittelman,
- Irit Avivi,
- Yakir Moshe
Affiliations
- Roi Gat
- 1 Tel Aviv Sourasky Medical Center, Department of Hematology, Tel Aviv, Israel
- Miri Neeman
- 1 Tel Aviv Sourasky Medical Center, Department of Hematology, Tel Aviv, Israel
- Shai Levi
- 1 Tel Aviv Sourasky Medical Center, Department of Hematology, Tel Aviv, Israel
- Mor Levi
- 1 Tel Aviv Sourasky Medical Center, Department of Hematology, Tel Aviv, Israel
- Nili Eilati
- 1 Tel Aviv Sourasky Medical Center, Department of Hematology, Tel Aviv, Israel
- Yotam Bronstein
- 1 Tel Aviv Sourasky Medical Center, Department of Hematology, Tel Aviv, Israel
- Tamir Shragai
- 1 Tel Aviv Sourasky Medical Center, Department of Hematology, Tel Aviv, Israel
- Tsipora Neuman
- 2 Tel Aviv University, Sackler Faculty of medicine, Tel Aviv, Israel
- Yafit Segman
- 1 Tel Aviv Sourasky Medical Center, Department of Hematology, Tel Aviv, Israel
- Roy Vitkon
- 1 Tel Aviv Sourasky Medical Center, Department of Hematology, Tel Aviv, Israel
- Moshe Mittelman
- 2 Tel Aviv University, Sackler Faculty of medicine, Tel Aviv, Israel
- Irit Avivi
- 1 Tel Aviv Sourasky Medical Center, Department of Hematology, Tel Aviv, Israel
- Yakir Moshe
- 1 Tel Aviv Sourasky Medical Center, Department of Hematology, Tel Aviv, Israel
- DOI
- https://doi.org/10.1097/01.HS9.0000969188.48112.10
- Journal volume & issue
-
Vol. 7
p. e4811210
Abstract
No abstracts available.